PE Tech Report


Like this article?

Sign up to our free newsletter

Novo Holdings participates in EUR110m first closing of Sound Bioventures Fund I

Novo Holdings, an international life sciences investor, today announced that it has invested in Sound Bioventures Fund I as cornerstone investor in the first close of EUR110 million.

Sound Bioventures will be investing in private biotech companies and will focus on companies with assets in clinical or late pre-clinical stages, primarily within rare diseases.

The fund will be managed by a founding team with extensive experience from venture investing and operational drug development. The team includes Casper Breum, who has a background from Novo Nordisk, Lundbeck and Lundbeckfonden Ventures, Johan Kördel who brings experience from Pharmacia, Biovitrum and Lundbeckfonden Ventures, and Bibhash Mukhopadhyay, with a background in J&J, AstraZeneca and NEA.

Like this article? Sign up to our free newsletter